Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.

Yu, Jing; Lee, Kang Bo; Chuanjie, Mu; Li, Qingdi; Abernathy, T. V.; Bostick-Bruton, Frieda; Reed, Eddie

doi:10.3892/ijo.16.3.555

Cited by 111 publications

(116 citation statements)

References 0 publications

Supporting

Mentioning

112

Contrasting

Unclassified

Order By: Relevance

“…Previously, Yu et al reported that this transition converts a common codon usage (AAC) to an infrequent codon usage (AAT), whereas frequency of use is reduced two-fold (1997). They also described that the ovarian cancer cells with codon 118 C→T polymorphism showed markedly reduced ERCC1 mRNA compared with cells without C→T transition (Yu et al, 2000). This could be possible explanation of the association between the ERCC1 codon 118 C→T transition and the ERCC1 activity.…”

Section: Discussionmentioning

confidence: 95%

“…Recently, it was noted that the codon 118 C/T polymorphism (rs11615) is associated with differential mRNA levels (Yu et al, 2000;Park et al, 2003) and has been found to be associated with shorter overall survival for advanced colorectal cancer patients treated with platinum-based chemotherapy (Park et al, 2003). So, we hypothesized that this polymorphism in ERCC1 might affect the platinum-resistance of EOC patients.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer

Kang

Ju²,

Kim³

et al. 2006

Exp Mol Med

View full text Add to dashboard Cite

ERCC1 is a DNA repair gene and has been associated with resistance to DNA damaging agents. In this study we hypothesized that a polymorphism of ERCC1 Asn118Asn (C→T) might affect the platinum-resistance of epithelial ovarian cancer patients to platinum-taxane chemotherapy administered postoperatively. Using the SNapShot assay, we assessed this polymorphism in ERCC1 in 60 ovarian cancer patients. Platinum-resistance was defined as progression on platinum-based chemotherapy or recurrence within 6 months of completing therapy. Although not significant, platinum-resistance was less frequently observed in patients with the C/T + T/T genotype (P = 0.064). Multivariate analysis showed that the C/T + T/T genotypes constituted an independent predictive factor of reduced risk of platinum-resistance in ovarian cancer (odds ratio 0.17, 95% confidence interval 0.04-0.74, P = 0.018, Fisher's exact test). No significant correlation was observed between overall survival and the ERCC1 polymorphism. Our results suggest that genotyping of the ERCC1 polymorphism Asn118Asn may be useful for predicting the platinum-resistance of epithelial ovarian cancer patients. However, these findings require prospective confirmation.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Introductionmentioning

confidence: 99%

Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer

Kang

Ju²,

Kim³

et al. 2006

Exp Mol Med

View full text Add to dashboard Cite

show abstract

“…5 The synonymous T19007C polymorphism at codon 118 (Asn118Asn) may be associated with a reduction in expression of ERCC1 mRNA levels and subsequently a decreased level of ERCC1 protein. 6 In recent years, many studies in cancer epidemiology focused on the associations between cancer risks and DNA-repair pathway gene SNPs, including genes in NER pathway. However, studies on the polymorphism of ERCC1 T19007C polymorphisms had shown conflicting results; studies on ERCC1 C8092A polymorphisms had shown different trends of risk in cancer, but none of the result was significant.…”

Section: Introductionmentioning

confidence: 99%

No association of ERCC1 C8092A and T19007C polymorphisms to cancer risk: a meta-analysis

et al. 2007

Eur J Hum Genet

View full text Add to dashboard Cite

ERCC1 (excision repair cross complementation group 1) is a subunit of the nucleotide excision repair complex, which can perform DNA strand incision correction of DNA damage. Association studies on the ERCC1 polymorphisms (C8092A and T19007C) in cancer had shown conflicting results. We performed a meta-analysis from all eligible case-control studies to assess the purported associations. Overall, the 19007C allele (3 853 patients and 4 349 controls) showed no significant effect on cancer risk compared to 19007T allele (P ¼ 0.39, odds ratio (OR) ¼ 0.95; 95% confidence interval (CI) 0.85 -1.06, P heterogeneity ¼ 0.001) in all subjects. Meta-analysis under other genetic contrasts did not reveal any significant association of T19007C to cancer in all subjects, Caucasians and Asians. The 19007C allele (2 279 patients and 2 808 controls) showed no significant effect on lung cancer risk compared to 19007T allele (P ¼ 0.72, OR ¼ 0.94, 95% CI 0.69-1.29, P heterogeneity ¼ 0.0001) in all subjects. No significant effect of 8092A allele (3 865 patients and 3 750 controls) on cancer risk in all subjects (P ¼ 0.85, OR ¼ 1.01, 95% CI 0.94 -1.08, P heterogeneity ¼ 0.92) and in Caucasians and Asians compare to 8092C. No evidences of association of C8092A (501 patients and 620 controls) to squamous cell carcinoma were found. The accumulated evidence indicated ERCC1 T19007C and C8092A might not be risk factors for cancer. Significant betweenstudy heterogeneity existed in T19007C, which arose from a study showing significant protecting effect of 19007C allele compare to 19007T allele in smokers. More studies based on larger, stratified case-control population should be required to further evaluate the role of ERCC1 C8092A and T19007C polymorphisms in different cancer, especially in smokers.

show abstract

“…Studies revealed that the synonymous C118T polymorphism affected the levels of mRNA and protein, thus leading to differential cisplatin sensitivity (Chen et al, 2000;Yu et al, 2000;Park et al, 2002). Nevertheless, a recent report failed to show an association between ERCC1 mRNA levels and codon 118 polymorphisms in epithelial ovarian cancer .…”

Section: Discussionmentioning

confidence: 99%

“…Excision repair crosscomplementation group 1 (ERCC1) is the lead enzyme in the nucleotide excision repair (NER) DNA repair pathway. Preclinical data suggests that the ERCC1 C8092A and C118T polymorphisms could affect the ERCC1 mRNA and protein levels, thus leading to different platinum sensitivity and increased DNA repair capacity (Chen et al, 2000;Yu et al, 2000;Park et al, 2002). ERCC1 polymorphisms have been reported to predict better response Kalikaki et al, 2009;Li et al, 2010) or survival in NSCLC patients treated with platinum-based chemotherapy Ryu et al, 2004;Zhou et al, 2004).…”

Section: Introductionmentioning

confidence: 99%

Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population

Hong

Wang

Zhang

et al. 2013

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Abstract:Objective: The aim of this study was to evaluate the association between the methylenetetrahydrofolate reductase (MTHFR) C677T excision repair cross-complementation group 1 (ERCC1) genetic polymorphisms and the clinical efficacy of gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC). Methods: A total of 135 chemonaive patients with unresectable advanced NSCLC were treated with gemcitabine/platinum regimens. The polymorphisms of MTHFR C677T, ERCC1 C8092A, and ERCC1 C118T were genotyped using the TaqMan methods. Results: The overall response rate was 28.9%. Patients with MTHFR CC genotype had a higher rate of objective response than patients with variant genotype (TT or CT) (41.2% versus 19.1%, P=0.01). Median time to progression (TTP) of patients with MTHFR CC genotype was longer than that of patients with variant genotype (7.6 months versus 5.0 months, P=0.003). No significant associations were obtained between ERCC1 C118T and C8092A polymorphisms and both response and survival. Conclusions: Our data suggest the value of MTHFR C677T polymorphism as a possible predictive marker of response and TTP in advanced NSCLC patients treated with gemcitabine/platinum.

show abstract

Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.

Cited by 111 publications

References 0 publications

Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer

Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer

No association of ERCC1 C8092A and T19007C polymorphisms to cancer risk: a meta-analysis

Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population

Contact Info

Product

Resources

About